Categories Earnings, Technology, U.S. Markets News

What to expect from Lam Research’s Q2 earnings report

Semiconductor companies will start their quarterly reporting starting from January 23. Lam Research (LRCX) will be one of them in this group that will be reporting its December quarter financial results on Wednesday, January 23 after the bell. Wall Street analysts estimate Lam Research to post earnings of $3.67 per share on revenue of $2.50 billion for its second quarter of 2019.

For the second quarter of 2019, the company had guided revenue to touch $2.5 billion (plus or minus $150 million) and earnings per share to be $3.65 (plus or minus 20 cents).

For the first quarter of 2019, Lam exceeded Street’s predictions. However, earnings dropped 3% to $3.36 per share and revenue declined 6% to $2.33 billion year-over-year.

According to SEMI, the global sales of new semiconductor manufacturing equipment are projected to increase by 9.7% to $62 billion in 2018, exceeding the historic high of $56.6 billion set in 2017. The equipment market is expected to contract 4% in 2019 but grow 20.7% to reach $71.9 billion, an all-time high.

Apart from Lam Research, other chipmakers that will be reporting their quarterly results on January 23 include Texas Instruments (TXN) and Xilinx (XLNX). These three companies’ quarterly results and their outlook, as well as their discussion on the China impact, will throw some light on other semiconductor stocks’ recently ended quarterly performance and their future.

With the chipmakers facing extreme pressure in 2018 forcing most of the chip stocks to bottom out, market experts hope that the recent rallies would hold momentum in the future. However, Apple (AAPL) cutting its forecast citing the Chinese economy considered to be a headwind for the semiconductor industry.

Shares of the Fremont, California-based chipmaker hit a 52-week low ($122.64) on December 26, 2018. Lam Research stock, which lost about 28% in the last 52-weeks period, rose about 5% during Friday’s mid-day trading session.

Lam Research stock rises on Q1 earnings beat

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top